Testosterondeficiëntie (TDS) is een zwaar
onderschat probleem, terwijl het zeer veel aspecten en zelfs de
levensverwachting negatief beïnvloedt. TDS wordt vooral in
verband gebracht met erectieproblemen, soms wordt ook nog gedacht
aan verlies van spiermassa. Minder bekend is dat er een grote
correlatie is tussen testosterondeficiëntie en metabool syndroom
(MS), met obesitas, verstoorde lipidenprofielen, hart- en
vaatziekten, trombose, naast insulineresistentie en diabetes, en
zelfs verhoogd risico op sommige kankers. Zowel TDS als MS zijn
elk geassocieerd met een hogere mortaliteit.
Beste bezoeker, u heeft geen toegang.
Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.
U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!
Auteur
Figuren
Verschenen in
Referenties
Schulman C. Testosterone and obesity. Pro Aging Europe Congress 10 maart 2013, Brussel.
Schulman C. Testosterone Deficiency: A Common, Unrecognised Syndrome? Eur Urol 2009; 772-777. www.europeanurology.com
Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008 Jan;93(1):68-75.
Araujo AB et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. Clin J Clin Endocrinol Metab. 2011 Oct;96(10):3007-19.
Muraleedharan V, Jones TH. Review: testosterone and the metabolic syndrome. Ther Adv Endocrinol Metabol 2010; 1:207- http://tae.sagepub.com/content/1/5/207
Khaw KT et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007 Dec 4;116(23):2694-70
Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013 Feb 1. [Epub ahead of print]
Wu FCW et al. Age-associated changes in hypothalamic–pituitary–testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013 http://www.emas.man.ac.uk/publications
Wu FC & the EMAS Group. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). Pol Merkur Lekarski. 2013 Jan;34(199):24-8.
Muraleedharan V, Jones TH. Testosterone and the metabolic syndrome. Ther Adv Endocrinol Metab. 2010 October; 1(5): 207–223.
Tylińska M, Broncel M. The relationship between testosterone deficiency and metabolic syndrome in obese men. Eur J Endocrinol 2012 http://www.emas.man.ac.uk/publications
Tirabassi G et al. Testosterone and cardiovascular risk. Intern Emerg Med. 2013 Mar 9. [Epub ahead of print]
Corona G et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011 Nov;165(5):687-701.
Giagulli VA et al. Testosterone Deficiency in Male: A Risk Factor for Heart Failure. Endocr Metab Immune Disord Drug Targets. 2013 Jan 15. [Epub ahead of print]
Carruthers M. Testosterone Deficiency Syndrome: Cellular and molecular mechanism of action. Curr Aging Sci. 2012 Dec 4. [Epub ahead of print]
De Pergola G et al. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. Metabolism. 1997 Nov;46(11):1287-93.
Traish AM, Saad F, Feeley RJ, Guay A. The dark side of testosterone deficiency III: Cardiovascular disease. J Androl. 2009 Sep-Oct;30(5):477-94.
Corona G, Maggi M et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011 Dec;34(6 Pt 1):528-40.
Vikan T, Schirmer H, Njølstad I, Svartberg J. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur J Endocrinol. 2010 Apr;162(4):747-54.
Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006 Mar 15;295(11):1288-99.
Svartberg J, Jenssen T, Sundsfjord J, Jorde R. The associations of endogenous testosterone and sex hormone-binding globulin with glycosylated hemoglobin levels, in community dwelling men. The Tromsø Study. Diabetes Metab. 2004 Feb;30(1):29-34.
Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006 Sep 20;24(27):4448-56.
Derweesh IH, Wake RW et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int. 2007 Nov;100(5):1060-5.
Carruthers M, Trinick TR, Jankowska E, Traish AM. Are the adverse effects of glitazones linked to induced testosterone deficiency? Cardiovasc Diabetol. 2008 Oct 15;7:30.
Brand JS, van der Schouw YT. Testosterone, SHBG and cardiovascular health in postmenopausal women. Int J Impot Res. 2010 Mar-Apr;22(2):91-104.
Maturana MA, Breda V, Lhullier F, Spritzer PM. Relationship between endogenous testosterone and cardiovascular risk in early postmenopausal women. Metabolism. 2008 Jul;57(7):961-5.
Demers LM. Androgen deficiency in women; role of accurate testosterone measurements. Maturitas. 2010 Sep;67(1):39-45.
Krapf JM, Simon JA. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Maturitas. 2009 Jul 20;63(3):213-9.
Davey DA. Androgens in women before and after the menopause and post bilateral oophorectomy: clinical effects and indications for testosterone therapy. Womens Health (Lond Engl). 2012 Jul;8(4):437-46.
Cappola AR, Xue QL, Fried LP. Multiple hormonal deficiencies in anabolic hormones are found in frail older women: the Women's Health and Aging studies. J Gerontol A Biol Sci Med Sci. 2009 Feb;64(2):243-8.
Basaria S, Dobs AS. Clinical review: Controversies regarding transdermal androgen therapy in postmenopausal women. J Clin Endocrinol Metab. 2006 Dec;91(12):4743-52
